Abstract
An 11-year-old boy with asthma had been receiving a controlled release theophylline preparation. He was prescribed fluvoxamine for a depressive disorder and within a week complained of severe headaches, tiredness and vomiting. His serum theophylline concentration had increased from 14.2 mg/L (shortly before fluvoxamine was started) to 27.4 mg/L. Fluvoxamine was withdrawn and theophylline concentrations decreased. Clomipramine was substituted for fluvoxamine with no further problems, and a later theophylline concentration was 13.7 mg/L. Competitive inhibition of hepatic microsomal enzymes by fluvoxamine may have been responsible for the elevated theophylline concentrations and toxicity observed in this case.
| Original language | English |
|---|---|
| Pages (from-to) | 460-462 |
| Number of pages | 3 |
| Journal | Drug Safety |
| Volume | 6 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1 Jan 1991 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver